# Peptides and biologics: PRLR hair-loss research

Edition: atlas-peptides-biologics/1. Evidence reviewed 2026-09-25; registry availability rechecked 2026-09-26. Status: provisional editorial review, not a formal RoB 2 or GRADE assessment. The clinical question is whether PRLR-targeted antibodies improve androgenetic alopecia in humans. Nutrition equivalence is a separate question without supporting human evidence identified in this bounded intake.

## Trial records and missing results

[ABS-201 HEADLINE, NCT07317544](https://clinicaltrials.gov/study/NCT07317544): randomized placebo-controlled escalation study, up to 227 planned adults with or without AGA, sponsor Absci Pty Ltd. The sponsor describes Phase 1/2a; registry phase fields are Phase 1 and Phase 2. Primary endpoint is safety; hair count/width at 26 weeks are secondary MAD outcomes. Participant, care-provider, investigator and outcome-assessor masking is registry-reported. Recruiting; no results posted at this review. Allocation concealment, attrition and prespecified result analyses remain unverified without full protocols/results.

[HMI-115, NCT06118866](https://clinicaltrials.gov/study/NCT06118866): randomized placebo-controlled Phase II in men with AGA, 192 enrolled, sponsor Hope Medicine (Nanjing) Co., Ltd. Primary endpoint is non-vellus hair-count change at 24 weeks. All four masking roles above are registry-reported. Completed November 2024; no results posted. Missing results do not establish success, failure or equivalence, and do not prove absence of every possible external report.

Effects and confidence intervals for these randomized comparisons remain unknown. No effect was replaced by zero. [Absci's August 2026 update](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) discusses blinded interim safety/PK and forecasts efficacy readouts; it is not a controlled hair-growth result.

## Classification and regulatory scope

[ABS-201](https://www.absci.com/abs-201-case-study/) and [HMI-115](https://hopemedinc.com/accesspolicy) are investigational PRLR monoclonal antibodies. They are distinct from short peptide drugs. [EMA's Ozempic record](https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic) identifies semaglutide as a GLP-1 receptor agonist with an EU type 2 diabetes indication. This is a glossary example, not an appraisal of semaglutide benefits/harms or nutrition equivalence. The stable ABS-201 identifier includes sponsor and target because unrelated neurotensin research uses the same short code.

## Mechanism and contrary evidence

[Foitzik et al., 2006, PMID 16507890](https://pubmed.ncbi.nlm.nih.gov/16507890/), DOI 10.2353/ajpath.2006.050468: human follicle culture supports prolactin effects on the hair cycle. Mainly occipital follicles, supraphysiological exposure and follicle-level replicates limit inference to AGA patient treatment. Full-paper methods describe 180 follicles from 12 donors; follicle count is not patient sample size.

[Lutz 2012, PMID 22870355](https://pubmed.ncbi.nlm.nih.gov/22870355/), DOI 10.4161/derm.19472: retrospective series of 40 women, predominantly diffuse shedding, with follow-up in 15 untreated patients. Did not support moderately elevated serum prolactin as a simple explanation for hair-loss severity/pattern/duration. Selection, confounding and no comparison group limit causal inference. This is indirect counterevidence: it tests neither male AGA nor local PRLR blockade.

[Kaufman et al. 1998, PMID 9777765](https://pubmed.ncbi.nlm.nih.gov/9777765/), DOI 10.1016/S0190-9622(98)70007-6: placebo-controlled finasteride trials support an androgen-dependent therapeutic pathway. They are not a PRLR comparator or proof of a single disease cause. A second successful treatment mechanism would not invalidate the androgen findings.

## Disputed occupancy comparison

[Absci's SEC-filed May 2026 presentation](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/finalcorporatepresentati.htm), slides 13-17, presents animal PK and preliminary modeled skin occupancy. These are not measured human scalp occupancy or a head-to-head clinical result.

[Hope Medicine's August 25 response](https://www.hopemedinc.com/cn/company-release-57), English section II, disputes the comparison and says AGA Phase Ib/II PK/occupancy data were not disclosed or supplied to Absci. Status: conflicting-sources. This records a company allegation, not a legal finding. Neither source is independent of the commercial dispute. The intake did not locate a response resolving it. Underdosing explanations and a universal occupancy threshold remain unestablished.

## Funding, interests and appraisal limits

Trial sponsors are industry entities, confirmed in their registries. Their interviews, decks and releases are one sponsor family per company; repeated statements are not independent replication. Specific analysis rights, complete financing terms and individual investigator disclosures remain not-verified.

Foitzik's paper declares German Research Foundation Pa 345/11-2 and German Federal Ministry of Education and Research support to R.P.; funder roles/complete interests were not independently verified. Lutz declares no potential conflicts, an article-declared statement; funding and funder role remain unverified. The finasteride abstract has a Merck Research Laboratories affiliation; full funding/interest audit was not completed. No funding conclusion is used as a substitute for design appraisal.

This is a bounded narrative intake with sequential Scout, Architect, Reviewer and Verifier passes by one agent, not independent clinical review. Review exposed phase labeling, missing results, source-family dependence, modeled target engagement and nutrition extrapolation. No hidden score, formal certainty grade or claim of a cure is assigned. Long-term efficacy, uncommon harms, fertility and lactation remain incompletely characterized. Libido reporting cannot substitute for reproductive assessment.

## Counterevidence search and re-review

On 2026-09-25, web search over PubMed, ClinicalTrials.gov and official sponsor sites used: `prolactin receptor antibody alopecia randomized HMI-115 ABS-201 results`; `site.pubmed.ncbi.nlm.nih.gov "HMI-115" alopecia`; `site.pubmed.ncbi.nlm.nih.gov "ABS-201"`; `site.pubmed.ncbi.nlm.nih.gov prolactin hair loss normal concentrations 2012 Lutz`; and sponsor-specific queries for the occupancy dispute. No comparable published randomized PRLR AGA result was located. That is a search limit, not a null outcome. No correction/retraction notice was seen in inspected records or targeted searches; full supplement/Crossmark/Retraction Watch audit remains incomplete.

A new primary publication, posted trial result, resolved source dispute or regulatory decision requires a new reviewed edition. The website preserves this review date and explicit gaps. Its food-first editorial stance does not change scientific conclusions or imply a dietary substitute for antibody blockade.